Vorinostat in combination with bortezomib in patients with advanced malignancies directly alters transcription of target genes

Cancer Chemotherapy and Pharmacology

Volumn 72, Issue 3, 2013, Pages 661-667

  Kolesar, Jill M ^a   Traynor, Anne M ^a   Holen, Kyle D ^a   Hoang, Tien ^a   Seo, Songwon ^a,b   Kim, Kyungmann ^a,b   Alberti, Dona ^a   Espinoza Delgado, Igor ^c   Wright, John J ^c   Wilding, George ^a   Bailey, Howard H ^a   Schelman, William R ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Bortezomib; Phase I; PS 341; SAHA; Vorinostat

Indexed keywords

BORTEZOMIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HEAT SHOCK PROTEIN 70; HISTONE H3; NUCLEAR RECEPTOR NUR77; PROTEIN KINASE B; PROTEIN P21; VORINOSTAT;

ADVANCED CANCER; AKT GENE; APOPTOSIS; ARTICLE; BLOOD SAMPLING; CHROMATIN IMMUNOPRECIPITATION; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE INCREASE; ERB1 GENE; ERB2 GENE; GENE EXPRESSION REGULATION; HSP70 GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MULTIPLE CYCLE TREATMENT; NUR77 GENE; P21 GENE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN DNA INTERACTION; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; TUMOR BIOPSY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY; BORONIC ACIDS; CHROMATIN IMMUNOPRECIPITATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; GENE EXPRESSION REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDROXAMIC ACIDS; LEUKOCYTES, MONONUCLEAR; NEOPLASMS; NUCLEAR RECEPTOR SUBFAMILY 4, GROUP A, MEMBER 1; PROTO-ONCOGENE PROTEINS C-AKT; PYRAZINES; TIME FACTORS; TRANSCRIPTION, GENETIC;

EID: 84883487790     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2242-6     Document Type: Article

References (17)

1. Kim HJ, Bae SC (2011) Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. Am J Transl Res 3(2):166-179
2. Di Marcotullio L, Canettieri G, Infante P, Greco A, Gulino A (2011) Protected from the inside: endogenous histone deacetylase inhibitors and the road to cancer. Biochim Biophys Acta 1815(2):241-252
3. Kavanaugh SM, White LA, Kolesar JM (2010) Vorinostat: a novel therapy for the treatment of cutaneous T-cell lymphoma. Am J Health Syst Pharm 67(10):793-797
4. Richon VM, Sandhoff TW, Rifkind RA, Marks PA (2000) Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA 97:10014-10019
5. Sandor V, Senderowicz A, Mertins S, Sackett D, Sausville E, Blagosklonny MV, Bates SE (2000) P21-dependent g (1) arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228. Br J Cancer 83:817-825
6. Sarfstein R, Bruchim I, Fishman A, Werner H (2011) The mechanism of action of the histone deacetylase inhibitor vorinostat involves interaction with the insulin-like growth factor signaling pathway. PLoS ONE 6(9):e24468
7. Yoon K, Lee SO, Cho SD, Kim K, Khan S, Safe S (2011) Activation of nuclear TR3 (NR4A1) by a diindolylmethane analog induces apoptosis and proapoptotic genes in pancreatic cancer cells and tumor. Carcinogenesis 32(6):836-842
8. Chen J, Fiskus W, Eaton K, Fernandez P, Wang Y, Rao R, Lee P, Joshi R, Yang Y, Kolhe R, Balusu R, Chappa P, Natarajan K, Jillella A, Atadja P, Bhalla KN (2009) Cotreatment with BCL-2 antagonist sensitizes cutaneous T-cell lymphoma to lethal action of HDAC7-Nur77-based mechanism. Blood 113(17):4038-4048 [Epub 2008 Dec 12]
9. Bruzzese F, Leone A, Rocco M, Carbone C, Piro G, Caraglia M, Di Gennaro E, Budillon A (2011) HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT. J Cell Physiol 226(9):2378-2390
10. Lin TY, Fenger J, Murahari S, Bear MD, Kulp SK, Wang D, Chen CS, Kisseberth WC, London CA (2010) AR-42, a novel HDAC inhibitor, exhibits biologic activity against malignant mast cell lines via down-regulation of constitutively activated Kit. Blood 115(21):4217-4225
11. Zhang QL, Wang L, Zhang YW, Jiang XX, Yang F, Wu WL, Janin A, Chen Z, Shen ZX, Chen SJ, Zhao WL (2009) The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis. Leukemia 23(8):1507-1514
12. Schelman WR, Kolesar J, Schell K, Marnocha R, Eickhoff J, Alberti D, Wilding G, Bailey H (2007) A phase I study of vorinostat in combination with bortezomib in refractory solid tumors. J Clin Oncol 25(18S):3573
13. Mossman D, Scott RJ (2011) Long term transcriptional reactivation of epigenetically silenced genes in colorectal cancer cells requires DNA hypomethylation and histone acetylation. PLoS ONE 6(8):e23127
14. Joly AL, Wettstein G, Mignot G, Ghiringhelli F, Garrido C (2010) Dual role of heat shock proteins as regulators of apoptosis and innate immunity. J Innate Immun 2(3):238-247
15. Powers MV, Jones K, Barillari C, Westwood I, van Montfort RL, Workman P (2010) Targeting HSP70: the second potentially druggable heat shock protein and molecular chaperone? Cell Cycle 9(8):1542-1550
16. Faraco G, Pancani T, Formentini L, Mascagni P, Fossati G, Leoni F, Moroni F, Chiarugi A (2006) Pharmacological inhibition of histone deacetylases by suberoylanilide hydroxamic acid specifically alters gene expression and reduces ischemic injury in the mouse brain. Mol Pharmacol 70(6):1876-1884
17. Mühlenberg T, Zhang Y, Wagner AJ, Grabellus F, Bradner J, Taeger G, Lang H, Taguchi T, Schuler M, Fletcher JA, Bauer S (2009) Inhibitors of deacetylases suppress oncogenic KIT signaling, acetylate HSP90, and induce apoptosis in gastrointestinal stromal tumors. Cancer Res 69(17):6941-6950